Press release
Epidermolysis Bullosa Market to Observe Impressive Growth by (2024-2034), Evaluates DelveInsight | Amryt Pharma, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, RegeneRx, Lenus
The Epidermolysis Bullosa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epidermolysis Bullosa pipeline products will significantly revolutionize the Epidermolysis Bullosa market dynamics.
DelveInsight's "Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Epidermolysis Bullosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Epidermolysis Bullosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Epidermolysis Bullosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epidermolysis Bullosa Market Insights [http://delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Epidermolysis Bullosa Market Report:
* The Epidermolysis Bullosa market size was valued at USD 2,400 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In November 2023, Krystal Biotech disclosed that the Marketing Authorization Application (MAA) submitted to the European Medicines Agency (EMA) Committee CHMP for VYJUVEK to address dystrophic epidermolysis bullosa (DEB) has been accepted and is presently undergoing CHMP scrutiny. An opinion from CHMP is expected in the latter part of 2024.
* In September, 2023, Abeona Therapeutics has filed a Biologics License Application (BLA) for EB101 with the FDA. Should it receive Priority Review designation, the company anticipates potential approval of the BLA in the second quarter of 2024.
* The exact number of individuals impacted by epidermolysis bullosa remains uncertain, as per Stanford Medicine (2023). However, an estimated 25,000 to 50,000 people in the United States are believed to be affected by this condition.
* The overall prevalent population of Epidermolysis Bullosa across the 7MM was approximately 47,000 cases in 2023. These cases are expected to rise during the study period from 2020 to 2034.
* In 2023, the prevalent population of epidermolysis bullosa in Japan was estimated to be around 2,000 cases. It is expected that these cases will increase by the year 2034.
* In 2023, the total prevalent cases of Epidermolysis Bullosa in the United States were approximately 31,000.
* Key Epidermolysis Bullosa Companies: Amryt Pharma, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, RegeneRx/ Lenus Therapeutics, Castle Creek Biosciences, Ishin Pharma, RHEACELL GmbH & Co. KG, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., TWi Biotechnology, Inc., Castle Creek Biosciences, Holostem Terapie Avanzate s.r.l., and others
* Key Epidermolysis Bullosa Therapies: FILSUVEZ, B-VEC, EB-101, FCX-007, RGN-137, D-Fi (dabocemagene autoficel), ISN001, APZ2-OTS, PTW-002, AGLE 102, ALLO-ASC-SHEET, AC-203, FCX-007, Transplantation, and others
Epidermolysis Bullosa Overview
Epidermolysis bullosa (EB) is a rare genetic disorder characterized by fragile skin that is prone to blistering and tearing even with minor friction or trauma. It is caused by mutations in genes responsible for producing proteins that help anchor the layers of skin together. As a result, individuals with EB have skin that is extremely delicate and prone to blistering, leading to painful open wounds and sores.
Get a Free sample for the Epidermolysis Bullosa Market Report:
https://www.delveinsight.com/report-store/epidermolysis-bullosa-market [https://www.delveinsight.com/report-store/epidermolysis-bullosa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Epidermolysis Bullosa Market
The dynamics of the Epidermolysis Bullosa market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"In June 2022, the European Commission (EC) approved FILSUVEZ for the treatment of partial-thickness wounds associated with dystrophic and junctional epidermolysis bullosa in patients six months and older"
Epidermolysis Bullosa Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Epidermolysis Bullosa Epidemiology Segmentation:
The Epidermolysis Bullosa market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
* Total Prevalence of Epidermolysis Bullosa
* Prevalent Cases of Epidermolysis Bullosa by severity
* Gender-specific Prevalence of Epidermolysis Bullosa
* Diagnosed Cases of Episodic and Chronic Epidermolysis Bullosa
Download the report to understand which factors are driving Epidermolysis Bullosa epidemiology trends @ Epidermolysis Bullosa Epidemiological Insights [http://delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermolysis Bullosa market or expected to get launched during the study period. The analysis covers Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Epidermolysis Bullosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Epidermolysis Bullosa Therapies and Key Companies
* FILSUVEZ: Amryt Pharma
* B-VEC: Krystal Biotech
* EB-101: Abeona Therapeutics
* FCX-007: Castle Creek Biosciences
* RGN-137: RegeneRx/ Lenus Therapeutics
* D-Fi (dabocemagene autoficel): Castle Creek Biosciences
* ISN001: Ishin Pharma
* APZ2-OTS: RHEACELL GmbH & Co. KG
* PTW-002: Phoenicis Therapeutics
* AGLE 102: Aegle Therapeutics
* ALLO-ASC-SHEET: Anterogen Co., Ltd.
* AC-203: TWi Biotechnology, Inc.
* FCX-007: Castle Creek Biosciences
* Transplantation: Holostem Terapie Avanzate s.r.l.
To know more about Epidermolysis Bullosa treatment, visit @ Epidermolysis Bullosa Medications [http://delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Epidermolysis Bullosa Market Drivers
* The rise in the prevalence of epidermolysis bullosa
* Robust clinical pipeline containing emerging drugs with novel RoA and MoA
* Gene and cell therapies are also in the clinical stages of development for the treatment of epidermolysis bullosa
* Increase funding support from organizations such as epidermolysis bullosa Research Partnership
Epidermolysis Bullosa Market Unmet Needs
* Challenges in diagnosis
* Lack of effective treatment
* Challenges in the clinical trial
* Poor disease understanding
Scope of the Epidermolysis Bullosa Market Report
* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Epidermolysis Bullosa Companies: Amryt Pharma, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, RegeneRx/ Lenus Therapeutics, Castle Creek Biosciences, Ishin Pharma, RHEACELL GmbH & Co. KG, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., TWi Biotechnology, Inc., Castle Creek Biosciences, Holostem Terapie Avanzate s.r.l., and others
* Key Epidermolysis Bullosa Therapies: FILSUVEZ, B-VEC, EB-101, FCX-007, RGN-137, D-Fi (dabocemagene autoficel), ISN001, APZ2-OTS, PTW-002, AGLE 102, ALLO-ASC-SHEET, AC-203, FCX-007, Transplantation, and others
* Epidermolysis Bullosa Therapeutic Assessment: Epidermolysis Bullosa current marketed and Epidermolysis Bullosa emerging therapies
* Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa market drivers and Epidermolysis Bullosa market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Epidermolysis Bullosa Unmet Needs, KOL's views, Analyst's views, Epidermolysis Bullosa Market Access and Reimbursement
Discover more about therapies set to grab major Epidermolysis Bullosa market share @ Epidermolysis Bullosa market forecast [http://delveinsight.com/sample-request/epidermolysis-bullosa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Epidermolysis Bullosa Market Report Introduction
2. Executive Summary for Epidermolysis Bullosa
3. SWOT analysis of Epidermolysis Bullosa
4. Epidermolysis Bullosa Patient Share (%) Overview at a Glance
5. Epidermolysis Bullosa Market Overview at a Glance
6. Epidermolysis Bullosa Disease Background and Overview
7. Epidermolysis Bullosa Epidemiology and Patient Population
8. Country-Specific Patient Population of Epidermolysis Bullosa
9. Epidermolysis Bullosa Current Treatment and Medical Practices
10. Epidermolysis Bullosa Unmet Needs
11. Epidermolysis Bullosa Emerging Therapies
12. Epidermolysis Bullosa Market Outlook
13. Country-Wise Epidermolysis Bullosa Market Analysis (2020-2034)
14. Epidermolysis Bullosa Market Access and Reimbursement of Therapies
15. Epidermolysis Bullosa Market Drivers
16. Epidermolysis Bullosa Market Barriers
17. Epidermolysis Bullosa Appendix
18. Epidermolysis Bullosa Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epidermolysis-bullosa-market-to-observe-impressive-growth-by-20242034-evaluates-delveinsight-amryt-pharma-krystal-biotech-abeona-therapeutics-castle-creek-biosciences-regenerx-lenus]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epidermolysis Bullosa Market to Observe Impressive Growth by (2024-2034), Evaluates DelveInsight | Amryt Pharma, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, RegeneRx, Lenus here
News-ID: 3472018 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Epidermolysis
Epidermolysis Bullosa Market to Reach USD 6.8 Billion by 2034
Epidermolysis bullosa (EB) is a group of rare, genetic skin disorders characterized by fragile skin that blisters and tears easily. Often referred to as "the butterfly skin disease," EB significantly impacts patients' quality of life and requires long-term supportive care. Historically, treatments were limited to wound management and pain control, but recent advancements in gene therapy, cell-based therapies, and biologics are opening new possibilities for disease-modifying interventions.
Download Full PDF Sample…
Epidermolysis Bullosa Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Epidermolysis Bullosa Research. Learn more about…
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 20 …
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including Epidermolysis Bullosa clinical trials and nonclinical stage products. It also covers the Epidermolysis Bullosa therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Epidermolysis Bullosa Market to Reach US$ 3,856.2 Million by 2033
Market Overview:
The 7 major epidermolysis bullosa markets reached a value of US$ 2,496.5 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 3,856.2 Million by 2033, exhibiting a growth rate (CAGR) of 4% during 2023-2033.
The report offers a comprehensive analysis of the epidermolysis bullosa market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as…
Singapore Dystrophic Epidermolysis Bullosa Treatment Market to Observe Strong De …
Dystrophic Epidermolysis Bullosa Treatment Market: Introduction
According to the report, the global dystrophic epidermolysis bullosa treatment market was valued over US$ 412 Mn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine,…
Epidermolysis Bullosa Market Insights, Share, Size, Companies, and Forecast 2032
DelveInsight's Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Epidermolysis Bullosa Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Epidermolysis Bullosa Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size…
